In the last 12 months, insiders at HOLOGIC INC ($HOLX) filed 279 transactions with the SEC: 1 open-market purchases totaling $300,760 and 24 sales totaling $31,694,272. Net insider sentiment: net selling.
HOLOGIC INC operates in the X-ray apparatus & tubes & related irradiation apparatus industry (Industrial Applications and Services sector).
Most Active Insiders
- MACMILLAN STEPHEN P (Chairman, President and CEO) — 37 transactions totaling $40,771,466
- Oberton Karleen Marie (Chief Financial Officer) — 23 transactions totaling $9,630,388
- Mitchell Essex D (Chief Operating Officer) — 20 transactions totaling $4,331,182
- GARRETT SCOTT T (Director) — 11 transactions totaling $3,234,122
- Stamoulis Christiana (Director) — 13 transactions totaling $1,767,936
View all SEC Filings for HOLOGIC INC (HOLX).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 27, 2026 | Liddy Anne M. | General Counsel | F | Common Stock | 185 | $75.36 | 28,052.0000 | 225,879,000 | 0.66% | 0.00% |
| Feb. 26, 2026 | Dockendorff Charles J | Director | A | Common Stock | 3190 | $0.00 | 21,996.0000 | 225,879,000 | 16.96% | 0.00% |
| Feb. 26, 2026 | HANTSON LUDWIG | Director | A | Common Stock | 3190 | $0.00 | 16,146.0000 | 225,879,000 | 24.62% | 0.00% |
| Feb. 26, 2026 | Madaus Martin D | Director | A | Common Stock | 3190 | $0.00 | 10,841.0000 | 225,879,000 | 41.69% | 0.00% |
| Feb. 26, 2026 | McMillan Wayde D. | Director | A | Common Stock | 3190 | $0.00 | 4,932.0000 | 225,879,000 | 183.12% | 0.00% |
| Feb. 26, 2026 | Mohtashami Nanaz | Director | A | Common Stock | 3190 | $0.00 | 7,371.0000 | 225,879,000 | 76.30% | 0.00% |
| Feb. 26, 2026 | Stamoulis Christiana | Director | A | Common Stock | 3190 | $0.00 | 50,526.0000 | 225,879,000 | 6.74% | 0.00% |
| Feb. 26, 2026 | Stewart Stacey D. | Director | A | Common Stock | 3190 | $0.00 | 8,358.0000 | 225,879,000 | 61.73% | 0.00% |
| Feb. 26, 2026 | Wendell Amy McBride | Director | A | Common Stock | 3190 | $0.00 | 25,784.0000 | 225,879,000 | 14.12% | 0.00% |
| Feb. 10, 2026 | Horvath Mark W. | President, Breast & Skeletal | F | Common Stock | 113 | $75.15 | 23,026.0000 | 225,879,000 | 0.49% | 0.00% |
| Jan. 30, 2026 | De Walt Diana | SVP, Human Resources | F | Common Stock | 4416 | $74.93 | 7,603.0000 | 225,879,000 | 36.74% | 0.00% |
| Jan. 30, 2026 | De Walt Diana | SVP, Human Resources | F | Common Stock | 4416 | $74.93 | 7,603.0000 | 225,879,000 | 36.74% | 0.00% |
| Dec. 12, 2025 | Schnittker Brandon | President, GYN Surgical | F | Common Stock | 90 | $75.00 | 17,512.0000 | 227,573,000 | 0.51% | 0.00% |
| Nov. 14, 2025 | COHN BENJAMIN JORDAN | Principal Accounting Officer | F | Common Stock | 187 | $74.15 | 17,884.0000 | 227,573,000 | 1.03% | 0.00% |
| Nov. 14, 2025 | Liddy Anne M. | General Counsel | F | Common Stock | 337 | $74.15 | 28,237.0000 | 227,573,000 | 1.18% | 0.00% |
| Nov. 14, 2025 | Mitchell Essex D | Chief Operating Officer | F | Common Stock | 1342 | $74.15 | 77,610.0000 | 227,573,000 | 1.70% | 0.00% |
| Nov. 14, 2025 | Oberton Karleen Marie | Chief Financial Officer | F | Common Stock | 1333 | $74.15 | 150,735.0000 | 227,573,000 | 0.88% | 0.00% |
| Nov. 14, 2025 | Schneiders Jennifer M | President, Diag. Solutions | F | Common Stock | 561 | $74.15 | 41,318.0000 | 227,573,000 | 1.34% | 0.00% |
| Nov. 14, 2025 | Schnittker Brandon | President, GYN Surgical | F | Common Stock | 178 | $74.15 | 17,602.0000 | 227,573,000 | 1.00% | 0.00% |
| Nov. 14, 2025 | Verstreken Jan | Group President, International | F | Common Stock | 196 | $74.15 | 134,039.0000 | 227,573,000 | 0.15% | 0.00% |
| Nov. 14, 2025 | MACMILLAN STEPHEN P | Chairman, President and CEO | F | Common Stock | 6874 | $74.15 | 2,570,666.0000 | 227,573,000 | 0.27% | 0.00% |
| Nov. 11, 2025 | Oberton Karleen Marie | Chief Financial Officer | F | Common Stock | 1449 | $74.60 | 152,068.0000 | 227,573,000 | 0.94% | 0.00% |
| Nov. 11, 2025 | Liddy Anne M. | General Counsel | F | Common Stock | 406 | $74.60 | 28,574.0000 | 227,573,000 | 1.40% | 0.00% |
| Nov. 10, 2025 | Liddy Anne M. | General Counsel | A | Common Stock | 17496 | $0.00 | 28,980.0000 | 227,573,000 | 152.35% | 0.01% |
| Nov. 7, 2025 | Liddy Anne M. | General Counsel | F | Common Stock | 288 | $74.10 | 11,484.0000 | 227,573,000 | 2.45% | 0.00% |
| Nov. 10, 2025 | Horvath Mark W. | President, Breast & Skeletal | A | Common Stock | 13458 | $0.00 | 23,139.0000 | 227,573,000 | 139.01% | 0.01% |
| Nov. 11, 2025 | Mitchell Essex D | Chief Operating Officer | F | Common Stock | 1701 | $74.60 | 78,952.0000 | 227,573,000 | 2.11% | 0.00% |
| Nov. 10, 2025 | Mitchell Essex D | Chief Operating Officer | A | Common Stock | 47106 | $0.00 | 80,653.0000 | 227,573,000 | 140.42% | 0.02% |
| Nov. 7, 2025 | Mitchell Essex D | Chief Operating Officer | F | Common Stock | 3927 | $74.10 | 33,547.0000 | 227,573,000 | 10.48% | 0.00% |
| Nov. 10, 2025 | Oberton Karleen Marie | Chief Financial Officer | A | Common Stock | 43741 | $0.00 | 153,517.0000 | 227,573,000 | 39.85% | 0.02% |
| Nov. 7, 2025 | Oberton Karleen Marie | Chief Financial Officer | F | Common Stock | 9427 | $74.10 | 109,776.0000 | 227,573,000 | 7.91% | 0.00% |
| Nov. 11, 2025 | Schneiders Jennifer M | President, Diag. Solutions | F | Common Stock | 702 | $74.60 | 41,879.0000 | 227,573,000 | 1.65% | 0.00% |
| Nov. 10, 2025 | Schneiders Jennifer M | President, Diag. Solutions | A | Common Stock | 30282 | $0.00 | 42,581.0000 | 227,573,000 | 246.22% | 0.01% |
| Nov. 7, 2025 | Schneiders Jennifer M | President, Diag. Solutions | F | Common Stock | 158 | $74.10 | 12,299.0000 | 227,573,000 | 1.27% | 0.00% |
| Nov. 11, 2025 | Schnittker Brandon | President, GYN Surgical | F | Common Stock | 289 | $74.60 | 17,780.0000 | 227,573,000 | 1.60% | 0.00% |
| Nov. 10, 2025 | Schnittker Brandon | President, GYN Surgical | A | Common Stock | 12113 | $0.00 | 18,069.0000 | 227,573,000 | 203.37% | 0.01% |
| Nov. 7, 2025 | Schnittker Brandon | President, GYN Surgical | F | Common Stock | 138 | $74.10 | 5,956.0000 | 227,573,000 | 2.26% | 0.00% |
| Nov. 11, 2025 | Verstreken Jan | Group President, International | F | Common Stock | 178 | $74.60 | 134,235.0000 | 227,573,000 | 0.13% | 0.00% |
| Nov. 10, 2025 | Verstreken Jan | Group President, International | A | Common Stock | 16823 | $0.00 | 134,413.0000 | 227,573,000 | 14.31% | 0.01% |
| Nov. 7, 2025 | Verstreken Jan | Group President, International | F | Common Stock | 1420 | $74.10 | 117,590.0000 | 227,573,000 | 1.19% | 0.00% |
| Nov. 11, 2025 | COHN BENJAMIN JORDAN | Principal Accounting Officer | F | Common Stock | 181 | $74.60 | 18,071.0000 | 227,573,000 | 0.99% | 0.00% |
| Nov. 10, 2025 | COHN BENJAMIN JORDAN | Principal Accounting Officer | A | Common Stock | 5047 | $0.00 | 18,252.0000 | 227,573,000 | 38.22% | 0.00% |
| Nov. 7, 2025 | COHN BENJAMIN JORDAN | Principal Accounting Officer | F | Common Stock | 1078 | $74.10 | 13,205.0000 | 227,573,000 | 7.55% | 0.00% |
| Nov. 11, 2025 | MACMILLAN STEPHEN P | Chairman, President and CEO | F | Common Stock | 6679 | $74.60 | 2,577,540.0000 | 227,573,000 | 0.26% | 0.00% |
| Nov. 10, 2025 | MACMILLAN STEPHEN P | Chairman, President and CEO | A | Common Stock | 169582 | $0.00 | 2,584,219.0000 | 227,573,000 | 7.02% | 0.07% |
| Nov. 7, 2025 | MACMILLAN STEPHEN P | Chairman, President and CEO | F | Common Stock | 50405 | $74.10 | 2,414,637.0000 | 227,573,000 | 2.04% | 0.02% |
| Nov. 4, 2025 | Verstreken Jan | Group President, International | A | Common Stock | 15196 | $0.00 | 119,010.0000 | 227,573,000 | 14.64% | 0.01% |
| Nov. 4, 2025 | COHN BENJAMIN JORDAN | Principal Accounting Officer | A | Common Stock | 2656 | $0.00 | 14,283.0000 | 227,573,000 | 22.84% | 0.00% |
| Nov. 4, 2025 | Horvath Mark W. | President, Breast & Skeletal | A | Common Stock | 2278 | $0.00 | 9,681.0000 | 227,573,000 | 30.77% | 0.00% |
| Nov. 4, 2025 | Mitchell Essex D | Chief Operating Officer | A | Common Stock | 9116 | $0.00 | 37,474.0000 | 227,573,000 | 32.15% | 0.00% |
| Nov. 4, 2025 | MACMILLAN STEPHEN P | Chairman, President and CEO | A | Common Stock | 83589 | $0.00 | 2,465,042.0000 | 227,573,000 | 3.51% | 0.04% |
| Nov. 4, 2025 | Oberton Karleen Marie | Chief Financial Officer | A | Common Stock | 17095 | $0.00 | 119,203.0000 | 227,573,000 | 16.74% | 0.01% |
| Oct. 20, 2025 | Stamoulis Christiana | Director | M | Non-qualified Stock Option (Right to Buy) | 7402 | $0.00 | 0.0000 | 227,573,000 | 100.00% | 0.00% |
| Oct. 20, 2025 | Stamoulis Christiana | Director | M | Common Stock | 7402 | $36.04 | 54,738.0000 | 227,573,000 | 15.64% | 0.00% |
| Oct. 20, 2025 | Stamoulis Christiana | Director | S | Common Stock | 7402 | $73.07 | 47,336.0000 | 227,573,000 | 13.52% | 0.00% |
| Sept. 22, 2025 | MACMILLAN STEPHEN P | Chairman, President and CEO | S | Common Stock | 77418 | $67.04 | 2,420,153.0000 | 228,186,000 | 3.10% | 0.03% |
| Sept. 22, 2025 | MACMILLAN STEPHEN P | Chairman, President and CEO | M | Non-qualified Stock Option (Right to Buy) | 138358 | $0.00 | 0.0000 | 228,186,000 | 100.00% | 0.06% |
| Sept. 22, 2025 | MACMILLAN STEPHEN P | Chairman, President and CEO | S | Common Stock | 38700 | $67.32 | 2,381,453.0000 | 228,186,000 | 1.60% | 0.02% |
| Sept. 22, 2025 | MACMILLAN STEPHEN P | Chairman, President and CEO | M | Common Stock | 138358 | $39.96 | 2,519,811.0000 | 228,186,000 | 5.81% | 0.06% |
| Sept. 22, 2025 | MACMILLAN STEPHEN P | Chairman, President and CEO | S | Common Stock | 22240 | $66.13 | 2,497,571.0000 | 228,186,000 | 0.88% | 0.01% |
| May 30, 2025 | Schnittker Brandon | Div. President, GYN Surgical | F | Common Stock | 69 | $62.17 | 6,094.0000 | 232,107,000 | 1.12% | 0.00% |
| May 7, 2025 | Madaus Martin D | Director | P | Common Stock | 5445 | $55.24 | 7,651.0000 | 232,107,000 | 246.83% | 0.00% |
| April 7, 2025 | McMillan Wayde D. | Director | A | Non-qualified Stock Option (Right to Buy) | 5171 | $0.00 | 5,171.0000 | 232,107,000 | 9999.99% | 0.00% |
| April 7, 2025 | McMillan Wayde D. | Director | A | Common Stock | 1742 | $0.00 | 1,742.0000 | 232,107,000 | 9999.99% | 0.00% |
| Feb. 26, 2025 | Mohtashami Nanaz | Director | A | Common Stock | 1864 | $0.00 | 4,181.0000 | 232,107,000 | 80.45% | 0.00% |
| Feb. 26, 2025 | HANTSON LUDWIG | Director | A | Common Stock | 1864 | $0.00 | 12,956.0000 | 232,107,000 | 16.80% | 0.00% |
| Feb. 26, 2025 | Madaus Martin D | Director | A | Non-qualified Stock Option (Right to Buy) | 5535 | $0.00 | 5,535.0000 | 232,107,000 | 9999.99% | 0.00% |
| Feb. 26, 2025 | Madaus Martin D | Director | A | Common Stock | 1864 | $0.00 | 2,206.0000 | 232,107,000 | 545.03% | 0.00% |
| Feb. 26, 2025 | Mohtashami Nanaz | Director | A | Non-qualified Stock Option (Right to Buy) | 5535 | $0.00 | 5,535.0000 | 232,107,000 | 9999.99% | 0.00% |
| Feb. 26, 2025 | HANTSON LUDWIG | Director | A | Non-qualified Stock Option (Right to Buy) | 5535 | $0.00 | 5,535.0000 | 232,107,000 | 9999.99% | 0.00% |
| Feb. 26, 2025 | Stamoulis Christiana | Director | A | Non-qualified Stock Option (Right to Buy) | 5535 | $0.00 | 5,535.0000 | 232,107,000 | 9999.99% | 0.00% |
| Feb. 26, 2025 | Wendell Amy McBride | Director | A | Common Stock | 1864 | $0.00 | 22,594.0000 | 232,107,000 | 8.99% | 0.00% |
| Feb. 26, 2025 | Wendell Amy McBride | Director | A | Non-qualified Stock Option (Right to Buy) | 5535 | $0.00 | 5,535.0000 | 232,107,000 | 9999.99% | 0.00% |
| Feb. 26, 2025 | Stewart Stacey D. | Director | A | Common Stock | 1864 | $0.00 | 5,168.0000 | 232,107,000 | 56.42% | 0.00% |
| Feb. 26, 2025 | Stewart Stacey D. | Director | A | Non-qualified Stock Option (Right to Buy) | 5535 | $0.00 | 5,535.0000 | 232,107,000 | 9999.99% | 0.00% |
| Feb. 26, 2025 | Stamoulis Christiana | Director | A | Common Stock | 1864 | $0.00 | 47,336.0000 | 232,107,000 | 4.10% | 0.00% |
| Feb. 26, 2025 | Dockendorff Charles J | Director | A | Non-qualified Stock Option (Right to Buy) | 5535 | $0.00 | 5,535.0000 | 232,107,000 | 9999.99% | 0.00% |
| Feb. 26, 2025 | Dockendorff Charles J | Director | A | Common Stock | 1864 | $0.00 | 18,806.0000 | 232,107,000 | 11.00% | 0.00% |
| Feb. 10, 2025 | Horvath Mark W. | Div. Pres., Breast & Skeletal | A | Non-qualified Stock Option (Right to Buy) | 2844 | $0.00 | 2,844.0000 | 232,107,000 | 9999.99% | 0.00% |
| Feb. 10, 2025 | Horvath Mark W. | Div. Pres., Breast & Skeletal | A | Common Stock | 958 | $0.00 | 7,057.0000 | 232,107,000 | 15.71% | 0.00% |
| Dec. 13, 2024 | Schnittker Brandon | Div. President, GYN Surgical | F | Common Stock | 90 | $73.65 | 6,163.0000 | 237,553,000 | 1.44% | 0.00% |
| Dec. 9, 2024 | Madaus Martin D | Director | A | Common Stock | 342 | $0.00 | 342.0000 | 237,553,000 | 9999.99% | 0.00% |
| Dec. 4, 2024 | Mitchell Essex D | Chief Operating Officer | M | Non-qualified Stock Option (Right to Buy) | 4526 | $0.00 | 0.0000 | 237,553,000 | 100.00% | 0.00% |
| Dec. 4, 2024 | Mitchell Essex D | Chief Operating Officer | M | Non-qualified Stock Option (Right to Buy) | 7505 | $0.00 | 0.0000 | 237,553,000 | 100.00% | 0.00% |
| Dec. 4, 2024 | Mitchell Essex D | Chief Operating Officer | M | Non-qualified Stock Option (Right to Buy) | 8915 | $0.00 | 2,972.0000 | 237,553,000 | 75.00% | 0.00% |
| Dec. 4, 2024 | Mitchell Essex D | Chief Operating Officer | M | Common Stock | 8915 | $71.13 | 52,813.0000 | 237,553,000 | 20.31% | 0.00% |
| Dec. 4, 2024 | Mitchell Essex D | Chief Operating Officer | M | Common Stock | 4526 | $45.61 | 36,393.0000 | 237,553,000 | 14.20% | 0.00% |
| Dec. 4, 2024 | Mitchell Essex D | Chief Operating Officer | M | Common Stock | 7505 | $68.35 | 43,898.0000 | 237,553,000 | 20.62% | 0.00% |
| Dec. 4, 2024 | Mitchell Essex D | Chief Operating Officer | M | Common Stock | 1956 | $40.97 | 31,867.0000 | 237,553,000 | 6.54% | 0.00% |
| Dec. 4, 2024 | Mitchell Essex D | Chief Operating Officer | S | Common Stock | 24856 | $76.34 | 27,957.0000 | 237,553,000 | 47.06% | 0.01% |
| Dec. 4, 2024 | Mitchell Essex D | Chief Operating Officer | M | Non-qualified Stock Option (Right to Buy) | 1956 | $0.00 | 0.0000 | 237,553,000 | 100.00% | 0.00% |
| Nov. 14, 2024 | Schneiders Jennifer M | President, Diag. Solutions | F | Common Stock | 507 | $77.54 | 12,096.0000 | 237,553,000 | 4.02% | 0.00% |
| Nov. 14, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | F | Common Stock | 6860 | $77.54 | 2,381,107.0000 | 237,553,000 | 0.29% | 0.00% |
| Nov. 14, 2024 | Verstreken Jan | Group President, International | F | Common Stock | 630 | $77.54 | 103,814.0000 | 237,553,000 | 0.60% | 0.00% |
| Nov. 14, 2024 | Schnittker Brandon | Div. President, GYN Surgical | F | Common Stock | 178 | $77.54 | 6,253.0000 | 237,553,000 | 2.77% | 0.00% |
| Nov. 14, 2024 | Oberton Karleen Marie | Chief Financial Officer | F | Common Stock | 1332 | $77.54 | 102,108.0000 | 237,553,000 | 1.29% | 0.00% |
| Nov. 14, 2024 | Mitchell Essex D | Chief Operating Officer | F | Common Stock | 1341 | $77.54 | 29,911.0000 | 237,553,000 | 4.29% | 0.00% |
| Nov. 14, 2024 | Griffin John M. | General Counsel | F | Common Stock | 1120 | $77.54 | 182,514.0000 | 237,553,000 | 0.61% | 0.00% |
| Nov. 14, 2024 | COHN BENJAMIN JORDAN | Principal Accounting Officer | F | Common Stock | 110 | $77.54 | 11,250.0000 | 237,553,000 | 0.97% | 0.00% |
| Nov. 14, 2024 | Anderson Erik S | Div. Pres., Breast & Skeletal | F | Common Stock | 390 | $77.54 | 23,231.0000 | 237,553,000 | 1.65% | 0.00% |
| Nov. 11, 2024 | Schnittker Brandon | Div. President, GYN Surgical | A | Common Stock | 2834 | $0.00 | 6,431.0000 | 237,553,000 | 78.79% | 0.00% |
| Nov. 11, 2024 | Verstreken Jan | Group President, International | A | Common Stock | 6298 | $0.00 | 104,444.0000 | 237,553,000 | 6.42% | 0.00% |
| Nov. 11, 2024 | Verstreken Jan | Group President, International | A | Non-qualified Stock Option (Right to Buy) | 18698 | $0.00 | 18,698.0000 | 237,553,000 | 9999.99% | 0.01% |
| Nov. 7, 2024 | Schnittker Brandon | Div. President, GYN Surgical | F | Common Stock | 138 | $79.29 | 3,597.0000 | 237,553,000 | 3.69% | 0.00% |
| Nov. 11, 2024 | COHN BENJAMIN JORDAN | Principal Accounting Officer | A | Non-qualified Stock Option (Right to Buy) | 3505 | $0.00 | 3,505.0000 | 237,553,000 | 9999.99% | 0.00% |
| Nov. 11, 2024 | Schnittker Brandon | Div. President, GYN Surgical | A | Non-qualified Stock Option (Right to Buy) | 8414 | $0.00 | 8,414.0000 | 237,553,000 | 9999.99% | 0.00% |
| Nov. 7, 2024 | Schneiders Jennifer M | President, Diag. Solutions | F | Common Stock | 157 | $79.29 | 6,430.0000 | 237,553,000 | 2.38% | 0.00% |
| Nov. 8, 2024 | Schneiders Jennifer M | President, Diag. Solutions | F | Common Stock | 125 | $78.76 | 6,305.0000 | 237,553,000 | 1.94% | 0.00% |
| Nov. 8, 2024 | Oberton Karleen Marie | Chief Financial Officer | F | Common Stock | 12598 | $78.76 | 93,993.0000 | 237,553,000 | 11.82% | 0.01% |
| Nov. 11, 2024 | Oberton Karleen Marie | Chief Financial Officer | A | Common Stock | 9447 | $0.00 | 103,440.0000 | 237,553,000 | 10.05% | 0.00% |
| Nov. 11, 2024 | Oberton Karleen Marie | Chief Financial Officer | A | Non-qualified Stock Option (Right to Buy) | 28047 | $0.00 | 28,047.0000 | 237,553,000 | 9999.99% | 0.01% |
| Nov. 7, 2024 | Mitchell Essex D | Chief Operating Officer | F | Common Stock | 422 | $79.29 | 24,614.0000 | 237,553,000 | 1.69% | 0.00% |
| Nov. 8, 2024 | Mitchell Essex D | Chief Operating Officer | F | Common Stock | 4383 | $78.76 | 20,231.0000 | 237,553,000 | 17.81% | 0.00% |
| Nov. 11, 2024 | Mitchell Essex D | Chief Operating Officer | A | Common Stock | 11021 | $0.00 | 31,252.0000 | 237,553,000 | 54.48% | 0.00% |
| Nov. 11, 2024 | Mitchell Essex D | Chief Operating Officer | A | Non-qualified Stock Option (Right to Buy) | 32722 | $0.00 | 32,722.0000 | 237,553,000 | 9999.99% | 0.01% |
| Nov. 7, 2024 | Griffin John M. | General Counsel | F | Common Stock | 592 | $79.29 | 186,635.0000 | 237,553,000 | 0.32% | 0.00% |
| Nov. 8, 2024 | Griffin John M. | General Counsel | F | Common Stock | 9299 | $78.76 | 177,336.0000 | 237,553,000 | 4.98% | 0.00% |
| Nov. 11, 2024 | Griffin John M. | General Counsel | A | Common Stock | 6298 | $0.00 | 183,634.0000 | 237,553,000 | 3.55% | 0.00% |
| Nov. 11, 2024 | Griffin John M. | General Counsel | A | Non-qualified Stock Option (Right to Buy) | 18698 | $0.00 | 18,698.0000 | 237,553,000 | 9999.99% | 0.01% |
| Nov. 7, 2024 | COHN BENJAMIN JORDAN | Principal Accounting Officer | F | Common Stock | 106 | $79.29 | 10,370.0000 | 237,553,000 | 1.01% | 0.00% |
| Nov. 8, 2024 | COHN BENJAMIN JORDAN | Principal Accounting Officer | F | Common Stock | 190 | $78.76 | 10,180.0000 | 237,553,000 | 1.83% | 0.00% |
| Nov. 11, 2024 | COHN BENJAMIN JORDAN | Principal Accounting Officer | A | Common Stock | 1180 | $0.00 | 11,360.0000 | 237,553,000 | 11.59% | 0.00% |
| Nov. 11, 2024 | Anderson Erik S | Div. Pres., Breast & Skeletal | A | Non-qualified Stock Option (Right to Buy) | 14023 | $0.00 | 14,023.0000 | 237,553,000 | 9999.99% | 0.01% |
| Nov. 11, 2024 | Anderson Erik S | Div. Pres., Breast & Skeletal | A | Common Stock | 4723 | $0.00 | 23,621.0000 | 237,553,000 | 24.99% | 0.00% |
| Nov. 8, 2024 | Anderson Erik S | Div. Pres., Breast & Skeletal | F | Common Stock | 1397 | $78.76 | 18,898.0000 | 237,553,000 | 6.88% | 0.00% |
| Nov. 7, 2024 | Anderson Erik S | Div. Pres., Breast & Skeletal | F | Common Stock | 344 | $79.29 | 20,295.0000 | 237,553,000 | 1.67% | 0.00% |
| Nov. 11, 2024 | Schneiders Jennifer M | President, Diag. Solutions | A | Common Stock | 6298 | $0.00 | 12,603.0000 | 237,553,000 | 99.89% | 0.00% |
| Nov. 11, 2024 | Schneiders Jennifer M | President, Diag. Solutions | A | Non-qualified Stock Option (Right to Buy) | 18698 | $0.00 | 18,698.0000 | 237,553,000 | 9999.99% | 0.01% |
| Nov. 7, 2024 | Oberton Karleen Marie | Chief Financial Officer | F | Common Stock | 1161 | $79.29 | 106,591.0000 | 237,553,000 | 1.08% | 0.00% |
| Nov. 7, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | F | Common Stock | 6214 | $79.29 | 2,416,737.0000 | 237,553,000 | 0.26% | 0.00% |
| Nov. 8, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | F | Common Stock | 68447 | $78.76 | 2,348,290.0000 | 237,553,000 | 2.83% | 0.03% |
| Nov. 11, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | A | Common Stock | 39677 | $0.00 | 2,387,967.0000 | 237,553,000 | 1.69% | 0.02% |
| Nov. 11, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | A | Non-qualified Stock Option (Right to Buy) | 117801 | $0.00 | 117,801.0000 | 237,553,000 | 9999.99% | 0.05% |
| Nov. 7, 2024 | Verstreken Jan | Group President, International | F | Common Stock | 601 | $79.29 | 103,074.0000 | 237,553,000 | 0.58% | 0.00% |
| Nov. 8, 2024 | Verstreken Jan | Group President, International | F | Common Stock | 4928 | $78.76 | 98,146.0000 | 237,553,000 | 4.78% | 0.00% |
| Nov. 5, 2024 | Verstreken Jan | Group President, International | A | Common Stock | 17780 | $0.00 | 103,675.0000 | 237,553,000 | 20.70% | 0.01% |
| Nov. 5, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | A | Common Stock | 118560 | $0.00 | 2,422,951.0000 | 237,553,000 | 5.14% | 0.05% |
| Nov. 5, 2024 | Anderson Erik S | Div. Pres., Breast & Skeletal | A | Common Stock | 4149 | $0.00 | 20,639.0000 | 237,553,000 | 25.16% | 0.00% |
| Nov. 5, 2024 | Griffin John M. | General Counsel | A | Common Stock | 20746 | $0.00 | 187,227.0000 | 237,553,000 | 12.46% | 0.01% |
| Nov. 5, 2024 | Mitchell Essex D | Chief Operating Officer | A | Common Stock | 11854 | $0.00 | 25,036.0000 | 237,553,000 | 89.93% | 0.00% |
| Nov. 5, 2024 | Oberton Karleen Marie | Chief Financial Officer | A | Common Stock | 23710 | $0.00 | 107,752.0000 | 237,553,000 | 28.21% | 0.01% |
| Aug. 29, 2024 | Oberton Karleen Marie | Chief Financial Officer | M | Common Stock | 26080 | $40.97 | 129,996.0000 | 238,081,000 | 25.10% | 0.01% |
| Aug. 29, 2024 | Oberton Karleen Marie | Chief Financial Officer | M | Non-qualified Stock Option (Right to Buy) | 6725 | $0.00 | 0.0000 | 238,081,000 | 100.00% | 0.00% |
| Aug. 29, 2024 | Oberton Karleen Marie | Chief Financial Officer | M | Non-qualified Stock Option (Right to Buy) | 26080 | $0.00 | 0.0000 | 238,081,000 | 100.00% | 0.01% |
| Aug. 29, 2024 | Oberton Karleen Marie | Chief Financial Officer | S | Common Stock | 52679 | $80.56 | 84,042.0000 | 238,081,000 | 38.53% | 0.02% |
| Aug. 29, 2024 | Oberton Karleen Marie | Chief Financial Officer | M | Common Stock | 6725 | $40.85 | 136,721.0000 | 238,081,000 | 5.17% | 0.00% |
| Aug. 6, 2024 | Schnittker Brandon | Div. President, GYN Surgical | S | Common Stock | 476 | $83.11 | 3,735.0000 | 238,081,000 | 11.30% | 0.00% |
| Aug. 1, 2024 | COHN BENJAMIN JORDAN | Principal Accounting Officer | S | Common Stock | 5093 | $81.99 | 10,476.0000 | 238,081,000 | 32.71% | 0.00% |
| July 30, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | M | Non-qualified Stock Option (Right to Buy) | 44039 | $0.00 | 0.0000 | 238,081,000 | 100.00% | 0.02% |
| July 30, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | S | Common Stock | 20228 | $82.32 | 2,304,391.0000 | 238,081,000 | 0.87% | 0.01% |
| July 30, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | S | Common Stock | 16177 | $81.44 | 2,324,619.0000 | 238,081,000 | 0.69% | 0.01% |
| July 30, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | S | Common Stock | 7634 | $80.60 | 2,340,796.0000 | 238,081,000 | 0.33% | 0.00% |
| July 30, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | M | Common Stock | 44039 | $26.21 | 2,348,430.0000 | 238,081,000 | 1.91% | 0.02% |
| July 17, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | M | Common Stock | 3672 | $26.21 | 2,308,063.0000 | 238,081,000 | 0.16% | 0.00% |
| July 17, 2024 | Stamoulis Christiana | Director | M | Non-qualified Stock Option (Right to Buy) | 9039 | $0.00 | 0.0000 | 238,081,000 | 100.00% | 0.00% |
| July 17, 2024 | Stamoulis Christiana | Director | S | Common Stock | 9039 | $79.50 | 45,472.0000 | 238,081,000 | 16.58% | 0.00% |
| July 17, 2024 | Stamoulis Christiana | Director | M | Common Stock | 9039 | $26.74 | 54,511.0000 | 238,081,000 | 19.88% | 0.00% |
| July 17, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | M | Non-qualified Stock Option (Right to Buy) | 3672 | $0.00 | 44,039.0000 | 238,081,000 | 7.70% | 0.00% |
| July 17, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | S | Common Stock | 3672 | $80.13 | 2,304,391.0000 | 238,081,000 | 0.16% | 0.00% |
| May 31, 2024 | Schnittker Brandon | Div. President, GYN Surgical | F | Common Stock | 67 | $73.78 | 4,211.0000 | 248,831,000 | 1.57% | 0.00% |
| May 23, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | G | Common Stock | 57875 | $0.00 | 2,304,042.0000 | 248,831,000 | 2.45% | 0.02% |
| April 22, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | G | Common Stock | 12000 | $0.00 | 2,304,042.0000 | 248,831,000 | 0.52% | 0.00% |
| April 19, 2024 | MACMILLAN STEPHEN P | Chairman, President and CEO | G | Common Stock | 12000 | $0.00 | 2,316,042.0000 | 248,831,000 | 0.52% | 0.00% |
| March 14, 2024 | GARRETT SCOTT T | Director | M | Common Stock | 7402 | $36.04 | 65,052.0000 | 248,831,000 | 12.84% | 0.00% |
| March 14, 2024 | GARRETT SCOTT T | Director | M | Non-qualified Stock Option (Right to Buy) | 9039 | $0.00 | 0.0000 | 248,831,000 | 100.00% | 0.00% |
| March 14, 2024 | GARRETT SCOTT T | Director | M | Common Stock | 9039 | $26.74 | 57,650.0000 | 248,831,000 | 18.59% | 0.00% |
| March 14, 2024 | GARRETT SCOTT T | Director | M | Non-qualified Stock Option (Right to Buy) | 7402 | $0.00 | 0.0000 | 248,831,000 | 100.00% | 0.00% |
| March 14, 2024 | GARRETT SCOTT T | Director | S | Common Stock | 16441 | $75.50 | 48,611.0000 | 248,831,000 | 25.27% | 0.01% |
| March 7, 2024 | Stamoulis Christiana | Director | A | Non-qualified Stock Option (Right to Buy) | 4536 | $0.00 | 4,536.0000 | 248,831,000 | 9999.99% | 0.00% |
| March 7, 2024 | Stamoulis Christiana | Director | A | Common Stock | 1572 | $0.00 | 45,472.0000 | 248,831,000 | 3.58% | 0.00% |
| March 7, 2024 | Stewart Stacey D. | Director | A | Non-qualified Stock Option (Right to Buy) | 4536 | $0.00 | 4,536.0000 | 248,831,000 | 9999.99% | 0.00% |
| March 7, 2024 | Stewart Stacey D. | Director | A | Common Stock | 1572 | $0.00 | 3,304.0000 | 248,831,000 | 90.76% | 0.00% |
| March 7, 2024 | Wendell Amy McBride | Director | A | Non-qualified Stock Option (Right to Buy) | 4536 | $0.00 | 4,536.0000 | 248,831,000 | 9999.99% | 0.00% |
| March 7, 2024 | Wendell Amy McBride | Director | A | Common Stock | 1572 | $0.00 | 20,730.0000 | 248,831,000 | 8.21% | 0.00% |
| March 8, 2024 | CRAWFORD SALLY | Director | M | Non-qualified Stock Option (Right to Buy) | 9039 | $0.00 | 0.0000 | 248,831,000 | 100.00% | 0.00% |
| March 7, 2024 | CRAWFORD SALLY | Director | A | Non-qualified Stock Option (Right to Buy) | 4536 | $0.00 | 4,536.0000 | 248,831,000 | 9999.99% | 0.00% |
| March 7, 2024 | GARRETT SCOTT T | Director | A | Non-qualified Stock Option (Right to Buy) | 4536 | $0.00 | 4,536.0000 | 248,831,000 | 9999.99% | 0.00% |
| March 7, 2024 | GARRETT SCOTT T | Director | A | Common Stock | 1572 | $0.00 | 48,611.0000 | 248,831,000 | 3.34% | 0.00% |
| March 7, 2024 | HANTSON LUDWIG | Director | A | Non-qualified Stock Option (Right to Buy) | 4536 | $0.00 | 4,536.0000 | 248,831,000 | 9999.99% | 0.00% |
| March 7, 2024 | HANTSON LUDWIG | Director | A | Common Stock | 1572 | $0.00 | 11,092.0000 | 248,831,000 | 16.51% | 0.00% |
| March 7, 2024 | Mohtashami Nanaz | Director | A | Non-qualified Stock Option (Right to Buy) | 4536 | $0.00 | 4,536.0000 | 248,831,000 | 9999.99% | 0.00% |
| March 7, 2024 | Mohtashami Nanaz | Director | A | Common Stock | 1572 | $0.00 | 2,317.0000 | 248,831,000 | 211.01% | 0.00% |
| March 8, 2024 | CRAWFORD SALLY | Director | M | Common Stock | 9039 | $26.74 | 141,966.0000 | 248,831,000 | 6.80% | 0.00% |
| March 8, 2024 | CRAWFORD SALLY | Director | S | Common Stock | 9039 | $76.40 | 132,927.0000 | 248,831,000 | 6.37% | 0.00% |
| March 7, 2024 | Dockendorff Charles J | Director | A | Common Stock | 1572 | $0.00 | 18,407.0000 | 248,831,000 | 9.34% | 0.00% |
| March 8, 2024 | Dockendorff Charles J | Director | S | Common Stock | 1465 | $76.21 | 16,942.0000 | 248,831,000 | 7.96% | 0.00% |
| March 7, 2024 | Dockendorff Charles J | Director | A | Non-qualified Stock Option (Right to Buy) | 4536 | $0.00 | 4,536.0000 | 248,831,000 | 9999.99% | 0.00% |
| March 7, 2024 | CRAWFORD SALLY | Director | A | Common Stock | 1572 | $0.00 | 132,927.0000 | 248,831,000 | 1.20% | 0.00% |
| Jan. 29, 2024 | Oberton Karleen Marie | Chief Financial Officer | S | Common Stock | 14940 | $75.00 | 103,916.0000 | 248,831,000 | 12.57% | 0.01% |
| Jan. 2, 2024 | Dockendorff Charles J | Director | S | Common Stock | 16017 | $72.00 | 16,835.0000 | 248,831,000 | 48.76% | 0.01% |
| Jan. 2, 2024 | Dockendorff Charles J | Director | M | Non-qualified Stock Option (Right to Buy) | 7551 | $0.00 | 0.0000 | 248,831,000 | 100.00% | 0.00% |
| Jan. 2, 2024 | Dockendorff Charles J | Director | M | Common Stock | 7551 | $38.44 | 32,852.0000 | 248,831,000 | 29.84% | 0.00% |
| Dec. 13, 2023 | Dunne Peter Paul | SVP, Human Resources | A | Common Stock | 1231 | $0.00 | 10,643.0000 | 248,831,000 | 13.08% | 0.00% |
| Dec. 13, 2023 | Dunne Peter Paul | SVP, Human Resources | A | Non-qualified Stock Option (Right to Buy) | 3554 | $0.00 | 3,554.0000 | 248,831,000 | 9999.99% | 0.00% |
| Dec. 11, 2023 | GARRETT SCOTT T | Director | S | Common Stock | 10000 | $68.71 | 47,039.0000 | 248,831,000 | 17.53% | 0.00% |
| Nov. 29, 2023 | MACMILLAN STEPHEN P | Chairman, President and CEO | M | Non-qualified Stock Option (Right to Buy) | 47711 | $0.00 | 47,711.0000 | 248,831,000 | 50.00% | 0.02% |
| Nov. 29, 2023 | MACMILLAN STEPHEN P | Chairman, President and CEO | S | Common Stock | 47711 | $70.41 | 2,304,042.0000 | 248,831,000 | 2.03% | 0.02% |
| Nov. 29, 2023 | MACMILLAN STEPHEN P | Chairman, President and CEO | M | Common Stock | 47711 | $26.21 | 2,351,753.0000 | 248,831,000 | 2.07% | 0.02% |
| Nov. 21, 2023 | Mitchell Essex D | Div. President, GYN Surgical | S | Common Stock | 7500 | $71.85 | 12,827.0000 | 248,831,000 | 36.90% | 0.00% |
| Nov. 14, 2023 | Oberton Karleen Marie | Chief Financial Officer | A | Non-qualified Stock Option (Right to Buy) | 25070 | $0.00 | 25,070.0000 | 248,831,000 | 9999.99% | 0.01% |
| Nov. 14, 2023 | MACMILLAN STEPHEN P | Chairman, President and CEO | A | Common Stock | 40832 | $0.00 | 2,304,042.0000 | 248,831,000 | 1.80% | 0.02% |
| Nov. 14, 2023 | MACMILLAN STEPHEN P | Chairman, President and CEO | A | Non-qualified Stock Option (Right to Buy) | 117829 | $0.00 | 117,829.0000 | 248,831,000 | 9999.99% | 0.05% |
| Nov. 14, 2023 | Oberton Karleen Marie | Chief Financial Officer | A | Common Stock | 8687 | $0.00 | 118,856.0000 | 248,831,000 | 7.89% | 0.00% |
| Nov. 14, 2023 | Verstreken Jan | Group President, International | A | Common Stock | 6950 | $0.00 | 85,895.0000 | 248,831,000 | 8.80% | 0.00% |
| Nov. 14, 2023 | Verstreken Jan | Group President, International | A | Non-qualified Stock Option (Right to Buy) | 20056 | $0.00 | 20,056.0000 | 248,831,000 | 9999.99% | 0.01% |
| Nov. 14, 2023 | Schneiders Jennifer M | President, Diag. Solutions | A | Common Stock | 3475 | $0.00 | 6,337.0000 | 248,831,000 | 121.42% | 0.00% |
| Nov. 14, 2023 | Schneiders Jennifer M | President, Diag. Solutions | A | Non-qualified Stock Option (Right to Buy) | 10028 | $0.00 | 10,028.0000 | 248,831,000 | 9999.99% | 0.00% |
| Nov. 14, 2023 | Mitchell Essex D | Div. President, GYN Surgical | A | Common Stock | 8687 | $0.00 | 20,327.0000 | 248,831,000 | 74.63% | 0.00% |
| Nov. 14, 2023 | Mitchell Essex D | Div. President, GYN Surgical | A | Non-qualified Stock Option (Right to Buy) | 25070 | $0.00 | 25,070.0000 | 248,831,000 | 9999.99% | 0.01% |
| Nov. 14, 2023 | Hellmann Elisabeth A | SVP, Human Resources | A | Common Stock | 1390 | $0.00 | 9,574.0000 | 248,831,000 | 16.98% | 0.00% |
| Nov. 14, 2023 | Hellmann Elisabeth A | SVP, Human Resources | A | Non-qualified Stock Option (Right to Buy) | 4011 | $0.00 | 4,011.0000 | 248,831,000 | 9999.99% | 0.00% |
| Nov. 14, 2023 | Griffin John M. | General Counsel | A | Common Stock | 6950 | $0.00 | 166,481.0000 | 248,831,000 | 4.36% | 0.00% |
| Nov. 14, 2023 | Griffin John M. | General Counsel | A | Non-qualified Stock Option (Right to Buy) | 20056 | $0.00 | 20,056.0000 | 248,831,000 | 9999.99% | 0.01% |
| Nov. 14, 2023 | COHN BENJAMIN JORDAN | Principal Accounting Officer | A | Common Stock | 1216 | $0.00 | 15,226.0000 | 248,831,000 | 8.68% | 0.00% |
| Nov. 14, 2023 | COHN BENJAMIN JORDAN | Principal Accounting Officer | A | Non-qualified Stock Option (Right to Buy) | 3509 | $0.00 | 3,509.0000 | 248,831,000 | 9999.99% | 0.00% |
| Nov. 14, 2023 | Anderson Erik S | Div. Pres., Breast & Skeletal | A | Common Stock | 3822 | $0.00 | 16,490.0000 | 248,831,000 | 30.17% | 0.00% |
| Nov. 14, 2023 | Anderson Erik S | Div. Pres., Breast & Skeletal | A | Non-qualified Stock Option (Right to Buy) | 11030 | $0.00 | 11,030.0000 | 248,831,000 | 9999.99% | 0.00% |
| Nov. 8, 2023 | COHN BENJAMIN JORDAN | Principal Accounting Officer | F | Common Stock | 190 | $68.27 | 14,227.0000 | 248,831,000 | 1.32% | 0.00% |
| Nov. 9, 2023 | Griffin John M. | General Counsel | F | Common Stock | 9375 | $67.20 | 159,531.0000 | 248,831,000 | 5.55% | 0.00% |
| Nov. 8, 2023 | MACMILLAN STEPHEN P | Chairman, President and CEO | F | Common Stock | 5442 | $68.27 | 2,329,021.0000 | 248,831,000 | 0.23% | 0.00% |
| Nov. 9, 2023 | MACMILLAN STEPHEN P | Chairman, President and CEO | F | Common Stock | 65811 | $67.20 | 2,263,210.0000 | 248,831,000 | 2.83% | 0.03% |
| Nov. 8, 2023 | Oberton Karleen Marie | Chief Financial Officer | F | Common Stock | 688 | $68.27 | 121,068.0000 | 248,831,000 | 0.57% | 0.00% |
| Nov. 9, 2023 | Oberton Karleen Marie | Chief Financial Officer | F | Common Stock | 10899 | $67.20 | 110,169.0000 | 248,831,000 | 9.00% | 0.00% |
| Nov. 8, 2023 | Verstreken Jan | Group President, International | F | Common Stock | 194 | $68.27 | 80,423.0000 | 248,831,000 | 0.24% | 0.00% |
| Nov. 9, 2023 | Verstreken Jan | Group President, International | F | Common Stock | 1478 | $67.20 | 78,945.0000 | 248,831,000 | 1.84% | 0.00% |
| Nov. 8, 2023 | Schneiders Jennifer M | President, Diag. Solutions | F | Common Stock | 121 | $68.27 | 3,036.0000 | 248,831,000 | 3.83% | 0.00% |
| Nov. 9, 2023 | Schneiders Jennifer M | President, Diag. Solutions | F | Common Stock | 174 | $67.20 | 2,862.0000 | 248,831,000 | 5.73% | 0.00% |
| Nov. 8, 2023 | Mitchell Essex D | Div. President, GYN Surgical | F | Common Stock | 335 | $68.27 | 13,940.0000 | 248,831,000 | 2.35% | 0.00% |
| Nov. 9, 2023 | Mitchell Essex D | Div. President, GYN Surgical | F | Common Stock | 2300 | $67.20 | 11,640.0000 | 248,831,000 | 16.50% | 0.00% |
| Nov. 8, 2023 | Hellmann Elisabeth A | SVP, Human Resources | F | Common Stock | 244 | $68.27 | 8,378.0000 | 248,831,000 | 2.83% | 0.00% |
| Nov. 9, 2023 | Hellmann Elisabeth A | SVP, Human Resources | F | Common Stock | 194 | $67.20 | 8,184.0000 | 248,831,000 | 2.32% | 0.00% |
| Nov. 8, 2023 | Griffin John M. | General Counsel | F | Common Stock | 602 | $68.27 | 168,906.0000 | 248,831,000 | 0.36% | 0.00% |
| Nov. 9, 2023 | COHN BENJAMIN JORDAN | Principal Accounting Officer | F | Common Stock | 217 | $67.20 | 14,010.0000 | 248,831,000 | 1.53% | 0.00% |
| Nov. 8, 2023 | Anderson Erik S | Div. Pres., Breast & Skeletal | F | Common Stock | 126 | $68.27 | 14,107.0000 | 248,831,000 | 0.89% | 0.00% |
| Nov. 9, 2023 | Anderson Erik S | Div. Pres., Breast & Skeletal | F | Common Stock | 1439 | $67.20 | 12,668.0000 | 248,831,000 | 10.20% | 0.00% |
| Nov. 7, 2023 | Hellmann Elisabeth A | SVP, Human Resources | F | Common Stock | 272 | $68.37 | 8,622.0000 | 248,831,000 | 3.06% | 0.00% |
| Nov. 6, 2023 | Verstreken Jan | Group President, International | A | Common Stock | 2438 | $0.00 | 80,864.0000 | 248,831,000 | 3.11% | 0.00% |
| Nov. 7, 2023 | Verstreken Jan | Group President, International | F | Common Stock | 247 | $68.37 | 80,617.0000 | 248,831,000 | 0.31% | 0.00% |
| Nov. 6, 2023 | MACMILLAN STEPHEN P | Chairman, President and CEO | A | Common Stock | 24133 | $0.00 | 2,338,437.0000 | 248,831,000 | 1.04% | 0.01% |
| Nov. 7, 2023 | MACMILLAN STEPHEN P | Chairman, President and CEO | F | Common Stock | 3974 | $68.37 | 2,334,463.0000 | 248,831,000 | 0.17% | 0.00% |
| Nov. 6, 2023 | Oberton Karleen Marie | Chief Financial Officer | A | Common Stock | 4633 | $0.00 | 122,496.0000 | 248,831,000 | 3.93% | 0.00% |
| Nov. 7, 2023 | Oberton Karleen Marie | Chief Financial Officer | F | Common Stock | 740 | $68.37 | 121,756.0000 | 248,831,000 | 0.60% | 0.00% |
| Nov. 7, 2023 | Schneiders Jennifer M | President, Diag. Solutions | F | Common Stock | 154 | $68.37 | 3,157.0000 | 248,831,000 | 4.65% | 0.00% |
| Nov. 6, 2023 | Mitchell Essex D | Div. President, GYN Surgical | A | Common Stock | 1463 | $0.00 | 8,807.0000 | 248,831,000 | 19.92% | 0.00% |
| Nov. 7, 2023 | Mitchell Essex D | Div. President, GYN Surgical | F | Common Stock | 384 | $68.37 | 8,423.0000 | 248,831,000 | 4.36% | 0.00% |
| Nov. 6, 2023 | Griffin John M. | General Counsel | A | Common Stock | 4145 | $0.00 | 170,100.0000 | 248,831,000 | 2.50% | 0.00% |
| Nov. 7, 2023 | Griffin John M. | General Counsel | F | Common Stock | 592 | $68.37 | 169,508.0000 | 248,831,000 | 0.35% | 0.00% |
| Nov. 7, 2023 | COHN BENJAMIN JORDAN | Principal Accounting Officer | F | Common Stock | 106 | $68.37 | 14,417.0000 | 248,831,000 | 0.73% | 0.00% |
| Nov. 6, 2023 | Anderson Erik S | Div. Pres., Breast & Skeletal | A | Common Stock | 853 | $0.00 | 11,164.0000 | 248,831,000 | 8.27% | 0.00% |
| Nov. 7, 2023 | Anderson Erik S | Div. Pres., Breast & Skeletal | F | Common Stock | 343 | $68.37 | 10,821.0000 | 248,831,000 | 3.07% | 0.00% |
| Sept. 20, 2023 | Mohtashami Nanaz | Director | A | Common Stock | 745 | $0.00 | 745.0000 | 0 | 9999.99% | 0.00% |
| Sept. 20, 2023 | Mohtashami Nanaz | Director | A | Non-qualified Stock Option (Right to Buy) | 2141 | $0.00 | 2,141.0000 | 0 | 9999.99% | 0.00% |
| Aug. 30, 2023 | MACMILLAN STEPHEN P | Chairman, President and CEO | G | Common Stock | 1064954 | $0.00 | 2,314,304.0000 | 0 | 31.51% | 0.00% |
| June 30, 2023 | Verstreken Jan | Group President, International | F | Common Stock | 322 | $80.97 | 78,426.0000 | 0 | 0.41% | 0.00% |
| June 15, 2023 | GARRETT SCOTT T | Director | S | Common Stock | 10000 | $79.72 | 57,039.0000 | 0 | 14.92% | 0.00% |
| May 5, 2023 | Mitchell Essex D | Div. President, GYN Surgical | S | Common Stock | 2390 | $83.73 | 7,212.0000 | 0 | 24.89% | 0.00% |
| March 9, 2023 | Dockendorff Charles J | Director | A | Non-qualified Stock Option (Right to Buy) | 4210 | $0.00 | 4,210.0000 | 0 | 9999.99% | 0.00% |
| March 9, 2023 | CRAWFORD SALLY | Director | A | Common Stock | 1465 | $0.00 | 131,355.0000 | 0 | 1.13% | 0.00% |
| March 9, 2023 | CRAWFORD SALLY | Director | A | Non-qualified Stock Option (Right to Buy) | 4210 | $0.00 | 4,210.0000 | 0 | 9999.99% | 0.00% |
| March 9, 2023 | Nawana Namal | Director | A | Non-qualified Stock Option (Right to Buy) | 4210 | $0.00 | 4,210.0000 | 0 | 9999.99% | 0.00% |
| March 9, 2023 | HANTSON LUDWIG | Director | A | Common Stock | 1465 | $0.00 | 9,520.0000 | 0 | 18.19% | 0.00% |
| March 9, 2023 | HANTSON LUDWIG | Director | A | Non-qualified Stock Option (Right to Buy) | 4210 | $0.00 | 4,210.0000 | 0 | 9999.99% | 0.00% |
| March 9, 2023 | GARRETT SCOTT T | Director | A | Common Stock | 1465 | $0.00 | 67,039.0000 | 0 | 2.23% | 0.00% |
| March 9, 2023 | GARRETT SCOTT T | Director | A | Non-qualified Stock Option (Right to Buy) | 4210 | $0.00 | 4,210.0000 | 0 | 9999.99% | 0.00% |
| March 9, 2023 | Dockendorff Charles J | Director | A | Common Stock | 1465 | $0.00 | 25,301.0000 | 0 | 6.15% | 0.00% |
| March 9, 2023 | Nawana Namal | Director | A | Common Stock | 1465 | $0.00 | 18,221.0000 | 0 | 8.74% | 0.00% |
| March 9, 2023 | Stamoulis Christiana | Director | A | Non-qualified Stock Option (Right to Buy) | 4210 | $0.00 | 4,210.0000 | 0 | 9999.99% | 0.00% |
| March 9, 2023 | Stamoulis Christiana | Director | A | Common Stock | 1465 | $0.00 | 43,900.0000 | 0 | 3.45% | 0.00% |
| March 9, 2023 | Stewart Stacey D. | Director | A | Non-qualified Stock Option (Right to Buy) | 4210 | $0.00 | 4,210.0000 | 0 | 9999.99% | 0.00% |
| March 9, 2023 | Stewart Stacey D. | Director | A | Common Stock | 1465 | $0.00 | 1,732.0000 | 0 | 548.69% | 0.00% |
| March 9, 2023 | Wendell Amy McBride | Director | A | Non-qualified Stock Option (Right to Buy) | 4210 | $0.00 | 4,210.0000 | 0 | 9999.99% | 0.00% |
| March 9, 2023 | Wendell Amy McBride | Director | A | Common Stock | 1465 | $0.00 | 19,158.0000 | 0 | 8.28% | 0.00% |
| March 1, 2023 | Anderson Erik S | Div. Pres., Breast & Skeletal | F | Common Stock | 381 | $79.06 | 10,311.0000 | 0 | 3.56% | 0.00% |
| Feb. 7, 2023 | COHN BENJAMIN JORDAN | Principal Accounting Officer | M | Non-qualified Stock Option (Right to Buy) | 9128 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 7, 2023 | COHN BENJAMIN JORDAN | Principal Accounting Officer | M | Common Stock | 9128 | $40.97 | 23,426.0000 | 0 | 63.84% | 0.00% |
| Feb. 7, 2023 | Dockendorff Charles J | Director | G | Common Stock | 1336 | $0.00 | 23,836.0000 | 0 | 5.31% | 0.00% |
| Feb. 7, 2023 | COHN BENJAMIN JORDAN | Principal Accounting Officer | S | Common Stock | 9128 | $85.28 | 14,298.0000 | 0 | 38.97% | 0.00% |
| Jan. 2, 2023 | Stewart Stacey D. | Director | A | Common Stock | 267 | $0.00 | 267.0000 | 0 | 9999.99% | 0.00% |
| Jan. 2, 2023 | Stewart Stacey D. | Director | A | Non-qualified Stock Option (Right to Buy) | 768 | $0.00 | 768.0000 | 0 | 9999.99% | 0.00% |